Acquisition by Tomasello Shawn of 35000 shares of Allovir subject to Rule 16b-3

ALVR Stock  USD 0.45  0.01  2.17%   
Slightly above 66% of Allovir's investor base is looking to short. The analysis of the overall investor sentiment regarding Allovir suggests that many traders are alarmed. Allovir's investing sentiment overview a quick insight into current market opportunities from investing in Allovir. Many technical investors use Allovir stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Filed transaction by Allovir Director. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at macroaxis.com
Allovir insider trading alert for acquisition of common stock by Tomasello Shawn, Director, on 6th of June 2024. This event was filed by Allovir with SEC on 2024-06-06. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Allovir's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Allovir's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Allovir Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Allovir can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Allovir Fundamental Analysis

We analyze Allovir's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Allovir using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Allovir based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Asset

Current Asset Comparative Analysis

Allovir is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.

Allovir Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Allovir stock to make a market-neutral strategy. Peer analysis of Allovir could also be used in its relative valuation, which is a method of valuing Allovir by comparing valuation metrics with similar companies.

Peers

Allovir Related Equities

AGIOAgios Pharm   9.55   
0%
80.0%
ANABAnaptysBio   3.79   
0%
32.0%
BDTXBlack Diamond   2.40   
0%
20.0%
CRNXCrinetics Pharmaceuticals   1.81   
0%
15.0%
STOKStoke Therapeutics   1.49   
0%
12.0%
AVTEAerovate Therapeutics   1.19   
0%
10.0%
ANEBAnebulo Pharmaceuticals   0.72   
0%
6.0%
CGEMCullinan Oncology   0.43   
0%
3.0%
MRUSMerus BV   0.07   
1.0%
0%
FDMT4D Molecular   0.31   
2.0%
0%
INBXInhibrx   0.41   
3.0%
0%
ACRVAcrivon Therapeutics,   0.85   
7.0%
0%
KRONKronos Bio   2.04   
17.0%
0%
MLYSMineralys Therapeutics,   2.22   
18.0%
0%
ADAGAdagene   2.37   
20.0%
0%
ANTXAN2 Therapeutics   3.38   
28.0%
0%
LYELLyell Immunopharma   11.84   
100.0%
0%

Additional Tools for Allovir Stock Analysis

When running Allovir's price analysis, check to measure Allovir's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allovir is operating at the current time. Most of Allovir's value examination focuses on studying past and present price action to predict the probability of Allovir's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allovir's price. Additionally, you may evaluate how the addition of Allovir to your portfolios can decrease your overall portfolio volatility.